人突触小体相关蛋白25单克隆抗体的制备及初步鉴定

目的:制备抗人突触小体相关蛋白25(SNAP25)的鼠源单克隆抗体。方法:利用大肠杆菌表达SNAP25蛋白,纯化后免疫BALB/c小鼠制备杂交瘤细胞,筛选针对SNAP25的阳性杂交瘤细胞株,鉴定抗体亚型;用杂交瘤细胞株制备腹水单抗,纯化后利用SDS-PAGE检测抗体纯度。结果:表达并纯化得到纯度大于90%的SNAP25蛋白,免疫小鼠后经2轮筛选得到12株阳性杂交瘤细胞株,其中抗体重链包括IgG1、IgG2型,轻链大部分为κ链;选择具有相对较高抗原结合活性的14号杂交瘤细胞株制备腹水,纯化后得到纯度大于90%的抗体。结论:获得1株高纯度的针对SNAP25的鼠源单克隆抗体,为肉毒毒素的检测奠定了基础。     

抗果蝇MRJ蛋白单克隆抗体的制备和鉴定

制备抗果蝇MRJ蛋白单克隆抗体可用于研究果蝇mrj的生物学功能,使用IPTG诱导重组质粒pET28a-mrj在大肠杆菌Rosetta中表达,重组蛋白经过Ni-IDA凝胶柱亲和纯化后免疫BALB/c小鼠。然后取免疫好的小鼠的脾脏细胞与小鼠骨髓瘤细胞SP2/0融合,经克隆和筛选获得了能分泌抗果蝇MRJ蛋白单克隆抗体的杂交瘤细胞株。腹水制备后获得单克隆抗体,通过ELISA和Western Blot对所获得的抗体进行鉴定,结果表明所制备单克隆抗体能够特异性结合于原核及真核细胞表达的MRJ蛋白,可用于研究mrj基因的生物学功能。     

抗人B7-H1单克隆抗体的制备和鉴定

目的:采用杂交瘤技术制备抗人B7-H1单克隆抗体,并对其进行鉴定。方法:经抗原免疫的小鼠脾细胞与小鼠骨髓瘤细胞以常规方法融合;用间接ELISA法筛选分泌抗体的杂交瘤细胞株;阳性克隆用有限稀释法获得稳定分泌抗人B7-H1单克隆抗体的杂交瘤细胞株;扩增杂交瘤细胞注射进小鼠腹腔后制备腹水;纯化腹水中的单克隆抗体并对其亚型进行鉴定;用间接ELISA法测抗体效价;将肺癌组织制成石蜡切片,用抗人B7-H1抗体进行免疫组化染色。结果:获得1株稳定分泌抗人B7-H1单克隆抗体的杂交瘤细胞株,所分泌的单抗类型为IgG1;抗体效价为1×108,纯化后的抗体含量为6.76g/L;免疫组化实验中,单抗可与肺癌组织表面的B7-H1蛋白特异地结合。结论:制备了人B7-H1单克隆抗体,为B7-H1检测试剂盒的研制奠定了基础。     

EpCAM蛋白的表达、纯化及其单克隆抗体的制备

目的:原核表达EpCAM蛋白并制备抗EpCAM特异性单克隆抗体,初步鉴定相应单克隆抗体的特性。方法:PCR扩增EpCAM基因胞外区,将目的基因亚克隆至载体pET-28a(+),转化至大肠埃希菌株BL21,IPTG诱导表达,组氨酸亲和层析法纯化表达产物。纯化蛋白免疫BALB/c小鼠,将成功免疫的小鼠脾细胞与骨髓瘤SP2/0细胞融合,经ELISA筛选得到分泌特异性抗EpCAM的单克隆抗体的细胞株,免疫BALB/c小鼠进一步制备相应的单克隆抗体,并通过Western blot(蛋白质印记)和FACS(流式细胞分析)鉴定单抗的特异性及生物学活性。结果:成功构建重组表达载体pET28a-EpCAM并在大肠杆菌中获得表达,经His-tag亲和层析法获得纯化的EpCAM重组蛋白。EpCAM重组蛋白免疫的BALB/c小鼠的脾细胞与SP2/0细胞融合、筛选,获得两株稳定分泌EpCAM抗体的杂交瘤细胞株,分别命名为4B2、2F2并免疫BALB/c小鼠获得相应的单克隆抗体。Western blot结果显示4B2腹水纯化所得单抗能够识别FaDu细胞系(人咽鳞癌细胞)中的EpCAM蛋白,但2F2未能识别FaDu细胞中的变性的EpCAM蛋白。FACS结果显示两者均能和FaDu细胞中天然的EpCAM蛋白结合。讨论:成功制备了抗EpCAM的单克隆抗体,并能够识别人咽鳞癌细胞系FaDu中表达的EpCAM,为进一步研究EpCAM抗体在肿瘤治疗中的作用提供基础。     

日本血吸虫重组信号蛋白14—3—3的纯化及单克隆抗体的制备

纯化日本血吸虫（中国大陆株）重组信号蛋白（rSj14—3—3）,并制备其单克隆抗体。以纯化后的rsj14-3—3蛋白为抗原免疫Balb／c小鼠,用杂交瘤技术制备抗rSj14-3-3的单克隆抗体,并通过ELISA方法和Westernblotting测定抗体的效价与特异性。获得了大量高纯度的rSj14-3-3蛋白：筛选出了能够稳定分泌抗rSj14．3．3单抗的杂交瘤细胞株3H6。单抗亚型为IgG1。实验依靠大肠杆菌表达系统高效表达了rSj14—3—3蛋白,并利用该蛋白制备了单克隆抗体．可用于今后血吸虫病免疫诊断的实验研究。     

HBV前S2蛋白单克隆抗体的制备和生物学特性的鉴定

目的克隆表达HBV前S2蛋白,用纯化的重组蛋白GST-S2免疫BALB/C小鼠,通过杂交瘤技术制备抗HBV前S2蛋白的单克隆抗体(mAb),并鉴定其特性.方法利用含双拷贝乙肝病毒adw2亚型基因全序列的质粒pEcob6,经PCR方法扩增出HBV前S2片段,在GST表达系统中表达,表达产物用谷胱甘肽亲和层析纯化后,用于免疫BALB/c小鼠,采用杂交瘤技术制备抗前S2蛋白的mAb,采用间接ELISA方法和Western blot进行mAb特异性鉴定;同时采用间接ELISA方法鉴定mAb相对亲和力.结果获得一株可分泌特异性mAb的杂交瘤细胞7A6;相对亲和力均在107以上.Western blot显示该株mAb能特异识别重组前S2蛋白.结论成功地制备出抗HBV前S2蛋白的一株mAb.     

活化相关分泌蛋白1单克隆抗体的制备及其在保守结构域鉴定中的应用

目的:制备重组活化相关分泌蛋白1(ASP-1)的单克隆抗体,并用其鉴定保守结构域。方法:用原核表达并纯化的重组ASP-1不加佐剂免疫BALB/c小鼠,采用杂交瘤技术及有限稀释传代法筛选稳定分泌特异性抗体的杂交瘤细胞株,制备单抗腹水后用间接ELISA进行抗体特异性鉴定和效价检测,利用肽结合ELISA和Western印迹鉴定单抗识别的保守结构域。结果:获得5株能稳定分泌抗ASP-1单克隆抗体的杂交瘤细胞株,且5株单抗的识别区域均为21~28氨基酸残基的保守性结构域。结论:制备了抗ASP-1的单克隆抗体,为深入研究ASP-1佐剂的活性功能区及作用机制提供了有效工具。     

牛呼吸道合胞体病毒核蛋白的表达及其单克隆抗体的制备

利用牛呼吸道合胞体病毒(BRSV)接种牛肺细胞(BL),提取病毒RNA。通过RT-PCR扩增BRSV的核蛋白基因,然后定向克隆到原核表达载体pET30a,获得重组表达质粒pET30a-N。将重组质粒转化表达菌BL21(DE3),经增菌培养和IPTG诱导以及SDS-PAGE和Western blot分析,成功表达出了核蛋白(N),其分子量约为49kDa。为制备BRSV核蛋白的单克隆抗体,用纯化的重组核蛋白免疫BALB/c小鼠,取免疫鼠脾细胞与SP2/0细胞融合。采用以BRSV为检测抗原的间接ELISA筛选阳性细胞克隆,经3次克隆纯化后获得2株稳定分泌抗N特异性MAb的杂交瘤细胞株,分别命名为2D12与4B10。用2D12与4B10杂交瘤细胞株接种BALB/c小鼠制备腹水,采用rN及BRSV包被的ELISA测得的效价分别是1×105和1×106及1×102和1×103。间接ELISA、Western blot、IFA试验表明两株杂交瘤细胞所分泌的MAb具有良好的反应性和特异性。经抗体亚类鉴定D12与4B10均为IgG1/κ。特异性试验表明单抗2D12与4B10均不与牛副流感病毒3型和牛病毒性腹泻病毒反应。所制备的D12与4B10可用于建立检测BRSV病原及抗体的诊断方法。     

抗人CD19单链抗体基因的构建、表达及功能测定

采用RT-PCR方法从分泌抗人类白细胞表面分化抗原CD19单克隆抗体的杂交瘤细胞中克隆出V_H和V_L可变区基因,再通过重叠延伸拼接（spliceoverlap extension）PCR方法在V_H和V_L可变区基因之间引入连接肽(Gly4Ser)3,体外构建抗人CD19单链抗体（抗CD19-ScFv）基因。将其克隆至表达载体PET28a并在大肠杆菌中表达。SDS-PAGE和Westernblot分析结果表明,抗CD19-ScFv在BL21（DE3）菌中获得表达,重组蛋白的相对分子量为27kD,表达产物以不溶性包涵体形式存在,经过溶解包涵体,镍柱亲和层析纯化和体外复性过程,获得了高纯度的单链抗体片段。流式细胞分析结果证实抗CD19ScFv可与人类白细胞表面的分化抗原CD19结合,保留了鼠源性单抗与CD19结合活性。抗人CD19-ScFv的构建与表达,为下一步针对B淋巴系统恶性肿瘤的靶向治疗奠定了基础。     

人源CT55蛋白原核表达及单克隆抗体的制备

为制备Cancer testis 55(CT55)单克隆抗体,需构建带有人源CT55片段的原核表达质粒,把该质粒转化Rosetta感受态进行原核表达并得到目的蛋白,蛋白质被纯化后免疫6周雌性BALB/c小鼠。按传统的单克隆抗体的制备方法,取小鼠脾细胞与骨髓瘤细胞(sp2/0)进行融合,经ELISA方法筛选及两次连续亚克隆,共获得多株能稳定分泌抗CT55蛋白单克隆抗体的杂交瘤细胞,如3D8B7B12、4C8E1C9、3D8C10G9等。ELISA及Western blot(WB)分析结果表明,筛选的细胞株均能产生单克隆抗体,且该抗体均分别能与原核表达及真核表达的CT55蛋白发生特异性结合。单克隆抗体可用于免疫荧光试验,且与P53发生互作的荧光主要位于细胞核边缘。结果表明,成功制备了针对人源CT55蛋白的单克隆抗体。CT55蛋白单克隆抗体的制备为今后肝癌、胃癌、结肠癌等癌症的快速的病原学诊断以及CT55蛋白的结构和功能研究奠定了物质基础。     

真核细胞人突变CD59的纯化及初步鉴定

目的:获得人突变CD59(hmCD59)蛋白,为后续研究提供必要的材料。方法:运用脂质体介导法,将含有hmCD59全长cDNA序列的重组pALTER质粒与pcDNA3质粒共转染CHO细胞,以G418筛选阳性克隆,以免疫荧光技术和SDS-PAGE检测hmCD59的表达,表达产物经Anti-FLAGM2亲和凝胶纯化后,以SDS-PAGE、Western印迹和ELISA对纯化产物进行鉴定。结果:hmCD59蛋白在转染后的CHO细胞表面稳定表达。SDS-PAGE结果表明,纯化的hmCD59的相对分子质量同预期结果一致。Western印迹和ELISA证实,纯化的hmCD59蛋白具有与抗CD59抗体结合的活性。结论:获得了电泳纯的hmCD59蛋白,为进一步对其进行抗体制备、功能研究及临床应用奠定了基础。     

Production of a recombinant anti-human CD4 single-chain variable-fragment antibody using phage display technology and its expression in Escherichia coli

Single-chain variable fragment (scFv) is a fusion protein of the variable regions of the heavy (VH) and light (VL) chains of immunoglobulin, connected with a short linker peptide of 10 to about 20 amino acids. In this study, the scFv of a monoclonal antibody against the third domain of human CD4 was cloned from OKT4 hybridoma cells using the phage display technique and produced in E. coli. The expression, production, and purification of anti-CD4 scFv were tested using SDS-PAGE and Western blot, and the specificity of anti-CD4 scFv was examined using ELISA. A 31 kDa recombinant anti-CD4 scFv was expressed and produced in bacteria, which was confirmed by SDS-PAGE and Western blot assays. Sequence analysis proved the ScFv structure of the construct. It was able to bind to CD4 in quality ELISA assay. The canonical structure of anti-CD4 scFv antibody was obtained using the SWISS_MODEL bioinformatics tool for comparing with the scFv general structure. To the best of our knowledge, this is the first report for generating scFv against human CD4 antigen. Engineered anti-CD4 scFv could be used in immunological studies, including fluorochrome conjugation, bispecific antibody production, bifunctional protein synthesis, and other genetic engineering manipulations. Since the binding site of our product is domain 3 (D3) of the CD4 molecule and different from the CD4 immunological main domain, including D1 and D2, further studies are needed to evaluate the anti-CD4 scFv potential for diagnostic and therapeutic applications.     

OAS1蛋白单克隆抗体的制备及其表征

目的:用OAS1蛋白免疫小鼠,获得OAS1特异性单克隆抗体,为OAS1的含量测定提供基础。方法:通过全基因合成的方法获得目的基因序列,转化大肠杆菌BL21细胞诱导His-OAS1及OAS1蛋白表达,纯化后用作抗原免疫小鼠,取脾融合,筛选稳定分泌抗体的阳性细胞株,制备并纯化单抗,通过SDS-PAGE,ELISA,Western blot等方法进行检测。结果:体外高效表达OAS1蛋白,并成功制备特异性单克隆抗体,效价在5×10^-11mol/L以上,亲和常数为3.37×10⁸ L·mol^-1。结论:获得高亲和力OAS1单克隆抗体,为其含量的检测奠定了基础。     

胰腺癌潜在肿瘤标志物的探索及在胰腺癌中的应用

目的:探索胰腺癌新的潜在标志物,建立夹心法ELISA体系,并初步应用于胰腺癌患者的血清检测。方法:应用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)技术对胰腺癌患者术前后血清进行分析,提纯分析差异蛋白并命名为DAP44,通过杂交瘤技术制备出抗DAP44单克隆抗体,用HRP标记法标记抗体,间接ELISA法检测抗体滴度,用制备出的抗体对胰腺癌组织和癌旁组织进行组化染色,采用夹心ELISA(DAS-ELISA)法制备抗DAP44检测试剂盒,检测胰腺癌病人和正常人血清DAP44值,比较两者差异。结果:对差异蛋白进行肽段测序和生物信息分析,并融合了3株能稳定分泌抗DAP44单克隆抗体的杂交瘤细胞(2D6H5,1E4D6,5B8H12),3株杂交瘤细胞分泌的抗体效价均在107以上,通过抗体配对筛选确定以2D6H5为包被抗体,1E4D6为酶标抗体时,DAS-ELISA法敏感性最高。两株抗体组化染色结果显示:癌组织DAP44表达量远高于癌旁。DAS-ELISA法标准曲线线性范围在0.78-25 ng/mL,检测下线为0.78 ng/mL,此方法检测到的胰腺癌病人和正常人血清DAP44平均含量分别为19.707±1.464和10.653±2.221,两者之间有统计学差异(P0.001)。结论:DAP44可能作为潜在的胰腺癌肿瘤标志物,建立的抗DAP44 DAS-ELISA法体系能够初步用于胰腺癌的临床诊断和疗效评估指标。     

Characterization of N-terminal amino acid sequence of monoclonal nonspecific suppressor factor.

Monoclonal nonspecific suppressor factor (MNSF), a product of a murine T cell hybridoma, suppresses the antibody response to lipopolysaccharide. In an attempt to clarify the N-terminal sequence, MNSF was prepared and purified by affinity chromatography with the use of an anti-MNSF monoclonal antibody (MO6), and reverse-phase high-pressure liquid chromatography. On the SDS-PAGE, the purified MNSF showed a single band with a molecular weight of 12,000. The N-terminal amino acid sequence of the protein was determined and showed no strong homology to any of the sequences of known biologically active proteins. However, the sequence revealed significant (60%) amino acid identity to transforming growth factor beta 2 (TGF beta 2).     

Development of Immunoreagents for Diagnostics of CagA‐Positive Helicobacter pylori Infections

Background: Helicobacter pylori strains expressing cytotoxic CagA protein are more likely to provoke severe gastric mucosal pathology and cause adenocarcinoma development than that lacking CagA. Determination of the CagA‐status of a pathogen, therefore, is regarded as informative approach in H. pylori infection diagnostics and disease risk prediction. Materials and Methods: Molecular cloning, recombinant protein expression in Escherichia coli, affinity chromatography, electrophoresis and commonly used techniques of hybridoma production and screening were used as well as different immunosorbent assays and Western blot procedures. Results: Four overlapping N‐terminally His₆‐tagged recombinant fragments of CagA that covered the entire CagA sequence were produced and purified. An ELISA for specific anti‐CagA serum antibodies detection was developed and evaluated. Utilizing recombinant fragments, the first set of monoclonal antibodies against CagA‐antigen was produced and characterized. Three antibodies recognized distinct linear epitopes inside conserved regions of the cytotoxin whereas the epitope of the forth antibody was mapped in the variable area of CagA. The monoclonal antibodies allowed discriminating CagA‐positive and CagA‐negative H. pylori strains by means of Western blot and immunosorbent assays. Conclusions: The use of recombinant protein technology allowed obtaining pure CagA antigen, thus providing new perspectives for development of immunodiagnostic reagents. The set of monoclonal antibodies is a valuable tool for determination of CagA‐status of H. pylori infection and for the investigation of cytotoxin molecule as well.     

Modulation of CD4 cell cytokine production by colon cancer-associated mucin

Mucins have been implicated in tumor-associated immunosuppression. The possibility that colon cancer mucin (CCM) may modulate T-helper 1 (TH1) activity was evaluated by investigating its effect on the production of interleukin-2 (IL-2) by CD4⁺ cells, a process that requires antigen-specific and costimulatory signals. Methods: CCM was purified from human colorectal cancer cells by gel-exclusion fast-pressure liquid chromatography. Cytokine production of purified CD4⁺ cells was evaluated at the protein and gene level in the presence of a phorbol ester or an anti-CD3 monoclonal antibody (mAb) plus mAb against the CD28 costimulatory receptor to mimic two-signal activation. Results: Soluble CCM, which contains mucins MUC2 as well as MUC1, inhibited IL-2 mRNA expression and secretion of CD4⁺ stimulated with a phorbol ester or an anti-CD3 mAb plus anti-CD28 mAb. Pretreatment of CD4⁺ cells with anti-CD28 mAb abrogated the suppressive effects of CCM on IL-2 production, and flow cytometry showed decreased binding of anti-CD28 mAb to its receptor in the presence of mucin. In addition, Ca²⁺ mobilization after T cell receptor cross-linking with anti-CD3 mAb was maintained in the presence of CCM. Although interferon γ production was also diminished, CCM did not induce a general inhibition of cytokine production, nor did it decrease cell viability. Macrophage inflammatory protein 1α production was up-regulated; the production of IL-10 and transforming growth factor β was unchanged. Conclusions: The results indicate that CCM can alter TH1 activity and suggest that the modulation of costimulatory interactions is involved. They provide another mechanism of immunosuppression mediated by these highly expressed tumor products. Received: 23 March 1999 / Accepted: 3 August 1999